Proof of concept and pre-commercialisation
of personalized liquid biopsies in cancer therapy - BiopSense
(BiopSense)


Main funder

Funder's project number: 812729


Funds granted by main funder (€)

  • 149 999,99


Funding program


Project timetable

Project start date: 01/09/2018

Project end date: 28/02/2020


Summary

Problem: Extremely high sensitivity is needed for the detection of cancer DNA during the follow-up of biological cancer medications.
Solution: We have identified a novel technology that enables very sensitive detection of single-nucleotide polymorphism (SNP) from blood, providing a fast protocol for point-of-care screening of liquid biopsies. Our diagnostics platform will consist of new chemistry and device, and is an open system for designing new diagnostic targets. This will enable that not only the cancer medication can be personalized, but also the follow-up of the medication can be customized and performed close to each patient. The technology is based on our invention (US patent allowed) developed in the ERC Co project, but will have additional inventions for automated sample preparation and lab-on-chip design, which may need extended patent shield.
Business model: To commercialise the technology, the new chemistry and device design will be compared with competing mass spectrometric (UltraSEEK) and microfluidics (Idylla) platforms. The method will be developed from phase TRL 3 to TRL 4 during the project and the devopment will continue by a spinoff and potential investors, together with partnering companies or out-licensed. New international service-based business for primer design and medical consultation is possible.
Market size: Along with the new biological drugs, cancer medication costs are currently achieving €20 billion worldwide, but without genetical screening the efficiency of the biological treatments remains below 30%. Primary genetical analysis of the cancer and personalized follow-up screening could remarkably decrease the cost as well as increase human well-being.


Principal Investigator


Primary responsible unit


Related publications


Last updated on 2021-19-07 at 13:56